Testimony to FDA Drug Safety and Risk Management and Endocrine and Metabolic Drugs Advisory Committees Regarding Rosiglitazone Safety
June 6, 2013
View as PDF.
View press release
Public Citizen argues that not only should the current restrictions on the use of the diabetes drug rosiglitazone (Avandia) not be lifted, the drug should be removed from the U.S. market given its unique risks and the absence of any unique benefits. Among older patients with diabetes, rosiglitazone is associated with a significantly higher risk of heart failure and death compared to pioglitazone.